Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors inside the central nervous system, conolidine modulates alternate molecular targets. A Science Advances study uncovered that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://anciusr678ula9.idblogz.com/profile